Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Relapsed Anaplastic Large Cell Lymphoma: early-phase trial registry

1 of 1 indexed Relapsed Anaplastic Large Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Relapsed Anaplastic Large Cell Lymphoma: 1 US clinical trial tracked, 1 recruiting.

Relapsed Anaplastic Large Cell Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 1 of these trials.

Enrollment posture brief

Registry condition relapsed-anaplastic-large-cell-lymphoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Relapsed Anaplastic Larg (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Relapsed Anaplastic Large Cell Lymphoma

Relapsed Anaplastic Large Cell Lymphoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Relapsed Anaplastic Large Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Relapsed Anaplastic Large Cell Lymphoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Mayo Clinic 1 trials

Named interventions

Most-linked intervention names on Relapsed Anaplastic Large Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Positron Emission Tomography Procedure
1 trials
Biopsy Procedure
1 trials
Computed Tomography Procedure
1 trials
Bone Marrow Biopsy Procedure
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Relapsed Anaplastic Large Cell Lymphoma trials. A trial with sites in several states counts in each.

Minnesota 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Relapsed Anaplastic Large Cell Lymphoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Relapsed Anaplastic Large Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mayo Clinic sponsors the most Relapsed Anaplastic Large Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Anaplastic Large Cell Lymphoma condition card totals 1 registered trials; most-linked intervention Positron Emission Tomography; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.